Physician

Albert V Chan

According to 2025 Medicare claims, Albert Chan (NPI: 1386641744) practices interventional cardiology in the Cleveland, OH market, with the plurality of this provider's patient population coming from Lorain, OH. This provider's primary affiliated billing organization is THE CLEVELAND CLINIC FOUNDATION (NPI: 1679525919; TIN: 340714585) and primary practice location at 44011-1390. Chan is affiliated with the Cleveland Clinic Medicare ACO, LLC (ACO ID: A2729), participating under the MSSP model.

Chan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,288 traditional Medicare patients, billed 2,207 HCPCS/CPT codes, and received $84,393 in Medicare payments. The top billing code was 99233 (Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes). Part D data shows 3,963 prescription claims across 669 beneficiaries totaling $743,041 in drug costs, led by Eliquis (Apixaban). Open Payments data shows 10 records totaling $17,599. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $67,946 to $743,041. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	888	1,468	$89,396
2016	829	1,344	$85,177
2017	737	1,236	$76,407
2018	638	1,129	$73,303
2019	645	1,316	$89,363
2020	528	1,021	$59,012
2021	968	1,643	$84,586
2022	1,021	1,706	$87,655
2023	1,298	2,116	$87,109
2024	1,288	2,207	$84,393

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	324	1,459	$67,946
2016	375	1,701	$113,090
2017	404	1,594	$92,349
2018	399	1,557	$106,975
2019	469	2,272	$170,517
2020	528	2,983	$275,379
2021	562	3,059	$352,246
2022	605	3,182	$474,077
2023	627	3,512	$620,265
2024	669	3,963	$743,041

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	86	112	$85
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	339	452	$66
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	326	327	$47
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	125	126	$12
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	514	644	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	241	13,754	$259,859
Repatha Sureclick	Evolocumab	130	8,946	$172,793
Jardiance	Empagliflozin	93	5,746	$110,967
Entresto	Sacubitril/Valsartan	51	2,810	$55,936
Praluent Pen	Alirocumab	42	2,314	$39,433

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	9	$940	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$16,659	Novartis Pharmaceuticals Corporation
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Albert V. Chan?

Tedicare shows public-source Medicare data for Albert V. Chan (NPI 1386641744), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Albert V. Chan have ACO affiliation data?

Albert V. Chan is shown with ACO affiliation data for Cleveland Clinic Medicare ACO, LLC (MSSP, ACO ID A2729).

What billing organization is linked to Albert V. Chan?

Albert V. Chan is linked to THE CLEVELAND CLINIC FOUNDATION (billing NPI 1679525919) in the available physician profile data.

Does Albert V. Chan have Open Payments data?

Albert V. Chan has 10 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.